Concepedia

David A. Rider

DA

Statistics

Publications

21

Citations

1.1K

H-Index

16

Active since

2003

Affiliations

University of Birmingham(Current)

National University of Singapore

Institute of Molecular and Cell Biology

Agency for Science, Technology and Research

Silence Therapeutics (United Kingdom)

David A. Rider is an author at University of Birmingham specializing in life sciences, cell biology, and immunology.

ORCID

Publications per year

2003–2024

21

Publications

21

Autocrine Fibroblast Growth Factor 2 Increases the Multipotentiality of Human Adipose-Derived Mesenchymal Stem Cells

David A. Rider, Christian Dombrowski, Amber A. Sawyer et al. · Stem Cells · 2008 · 153 citations · Full text

, , +13

Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)

Steven E. Nissen, Qiuqing Wang, Stephen J. Nicholls et al. · JAMA · 2024 · 109 citations · Full text

, , +17

FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis

Jack Leslie, Ben Millar, Alicia del Carpio Pons et al. · JCI Insight · 2020 · 102 citations · Full text

, , +15

Altered T-Cell Function in Schizophrenia: A Cellular Model to Investigate Molecular Disease Mechanisms

Rachel Craddock, Helen Lockstone, David A. Rider et al. · PLoS ONE · 2007 · 96 citations · Full text

, , +17

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)

Steven E. Nissen, Kathy Wolski, Gerald F. Watts et al. · JAMA · 2024 · 77 citations · Full text

, , +17

1–5 of 21